- Open Access
Evaluation of specific humoral immune response and cross reactivity against Mycobacterium tuberculosis antigens induced in mice immunized with liposomes composed of total lipids extracted from Mycobacterium smegmatis
© de los Angeles García et al; licensee BioMed Central Ltd. 2013
Published: 25 February 2013
The development of a new tuberculosis (TB) vaccine has become one of the main objectives of the scientific community. Protein antigens have been widely explored as subunit TB vaccines, however lipid antigens could be equally important to be used or included in such a vaccine. The aim of this study was to demonstrate the potential of a liposome formulation composed of an extract of lipids from Mycobacterium smegmatis (Ms) as a TB vaccine candidate. We evaluated the immunogenicity of this formulation as well as the cross reactive response against antigens from Mycobacterium tuberculosis (MTb) in BALB/c mice. We determined the anti-liposome IgG response in sera from TB patients and from healthy subjects who displayed a positive (PPD+) or negative (PPD-) tuberculin skin test. A significant increase in anti-liposome IgG (p<0.05) was detected in animals immunized with Bacille Calmette-Guérin (BCG) compared with all groups, and in the group immunized with liposomes from Ms (LMs) compared to animals immunized with either LMs adjuvanted with aluminium (LMs-A) or the negative control group (phosphate buffered saline, PBS) respectively. With respect to the cross reactive response against a cocktail of cell wall antigens (CWA) from MTb, significantly higher IgG levels were observed in animals immunized with BCG and LMs compared to negative controls and either, aluminium-adjuvanted liposomes (LMs-A) or montanide (LMs-M) (p<0.05). Furthermore, the anti-liposome IgG response was significantly superior in sera from pulmonary TB patients compared to PPD+ and PPD- healthy subjects (p<0.001) suggesting the expression of these antigens in vivo during active MTb infection. The results obtained provide some evidence for the potential use of liposomes containing total lipid extracts of Ms as a TB vaccine candidate.
TB remains one of the infectious diseases that cause great morbidity and mortality worldwide. BCG, the current vaccine against TB offers poor or no protection against the most common clinical form of the disease, pulmonary TB in adults. It has shown variability in efficacy ranging from 0% to 80 % in several clinical trials around the world . Worst still, the epidemiological situation of this disease is worsening in many parts of the world. Therefore, there is an urgent need for a new or improved TB vaccine.
It has previously been shown that liposome formulations composed of total lipid extracts from Ms possess immune-adjuvant properties [2, 3]. It is therefore important to study the potential of such formulations as immunoprophylactic tools against TB, considering the fact that there is a high level of antigenic and genomic homology between Ms and MTb  and that there are great similarities in the lipid components of their cell walls.They have similar mechanisms of cell wall synthesis  and glycopeptidolipids of Ms recognize the same receptors as those of MTb .
This paper is an initial attempt to demonstrate the potential of a liposome formulation composed of total lipid extract from Ms as a possible TB vaccine candidate.
An evaluation of the anti-LMs specific IgG response and the cross-reactive IgG response against CWA from MTb in BALB/c mice immunized with LMs was carried out. Additionally, the anti-LMs specific IgG response in sera of TB patients as well as that of PPD+ and PPD- healthy subjects was determined.
Materials and methods
Ms mc2155 strain  (from the collection of the National Reference Laboratory of Tuberculosis, Pedro Kouri Institute, Cuba) was used. Cultures were grown in 1% (w/v) yeast extract (Merk, Germany), 0.5% (v/v) glycerol (Riedel de Haen, Germany), 0.4% (v/v) Tween 80 (Fluka, Germany), in 8% nutrient broth (Biocen, Cuba) for 48h with agitation (200 rpm) at 37ºC. The purity of the culture was evaluated by Ziehl-Neelsen staining .
Total lipid extraction from Ms was accomplished using the technique described by Bligh and Dyer  and the liposomes containing these lipids were obtained by the dehydration-rehydration method . The size of the vesicles was determined by transmission electron microscopy (TEM) and dynamic light scattering using a Brookhaven ZetaPlus (Brookhaven Instruments Worcs, UK).
Fifty female BALB/c mice (6-8 weeks) were used in the experiments. The procedure was carried out according to the international regulations for laboratory animal experimentation . Five groups of animals (n=10) were inoculated subcutaneously with either PBS; BCG, (Moreau strain, EPB ”Carlos J. Finlay”, Cuba) (106 CFU); LMs composed of 1mg of total lipids from Ms; LMs-A (LMs 1mg + alum Alhydrogel, Sigma, 1 mg) or LMs-M (LMs 1mg + Montanide, Seppicc, France). Two doses at 0 and 21 days were administered. The group immunized with BCG only received one dose on day 0. Blood samples were collected 42 days after the first immunization. The blood was centrifuged and the sera stored at -20ºC until use.
Sera from TB patients, PPD+ and PPD- healthy subjects were collected from the Universiti Sains Malaysia Hospital (HUSM). The protocols of the study were conducted according to the ethical guidelines as approved by the Human Ethics Committee of USM and written informed consent from participants was obtained.
An indirect ELISA was performed to measure the anti-LMs IgG response. Briefly, the plates were coated with 10µg/mL of the LMs formulation for 16h at 4°C and sera from mice were diluted at 1:50 and incubated for 1h at 37°C. A HRP conjugated rabbit anti mouse IgG (Sigma) at a dilution of 1:3000 was used and incubated for 1h at 37°C. The reaction was developed with a solution (100 µl /well) of o-phenylendiamine (OPD; Sigma) (5 mg in 12.5 ml 0.1 M sodium citrate buffer, pH 5 + 5 µl 30% (v/v) H2O2). After 20 to 30 min the reaction was stopped with 2N H2SO4 (50µl/well) and the absorbance was read at 492nm. To evaluate the cross-reactivity against the cell wall antigens (CWA) of MTb, a cocktail of these antigens was used to coat the ELISA plate at a concentration of 10µg/mL for 16h at 4°C.
A similar procedure was also followed to measure the anti-LMs IgG response in sera from TB patients, PPD+ and PPD- healthy subjects except that the secondary antibody used was a HRP conjugated rabbit anti human IgG (Sigma) at 1:6000 dilution.
Results and discussions
Using the described method, liposomes of between 50 to 200 nm were obtained (data not shown). The composition of the liposomes were deduced to consist of phosphatidylethanolamine, phosphatidylglycerol, cardiolipin, phosphatidylinositol and phosphatidylinositol mannosides, based on a similar methodology used by Faisal et al .
The cross-reactive response observed in the group immunized with LMs suggests that there are great structural antigenic similarities between MTb and Ms.
Immunization with LMs could be a promising strategy to elicit immune responses against antigens presented to the immune system during MTb infection in vivo.
This is the first report studying the potential of liposomes composed of total lipids of Ms as a possible TB vaccine candidate. Here the vector of the vaccine is also a relevant antigenic structure demonstrated by the capability of this formulation to induce specific IgG response and cross-reactivity against MTb in BALB/c mice. In addition, components of the liposome formulation were recognized by sera from TB patients suggesting the possible presence of these epitopes in MTb during active TB. These results support the future evaluation of LMs as an experimental vaccine candidate against TB.
This work was supported by the Ministry of Science, Technology and Innovation, Malaysia (10-01-05-MEB002), the Ministry of Higher Education, Malaysia LRGS Grant (203.PSK.6722001) and the Ministry of Science and Technology, Cuba. The authors thank Hajar Fauzan Bin Ahmad and Nur Hidayati Mohd Balia for their support in obtaining patients samples.
This article has been published as part of BMC Immunology Volume 14 Supplement 1, 2013: Proceedings from Delivery Systems and Current strategies to drug design. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcimmunol/supplements/14/S1.
- Orme IM: Beyond BCG: the potencial for a more effective TB vaccine. Mol. Med. Today. 1999, 5: 487-92. 10.1016/S1357-4310(99)01594-4.View ArticlePubMedGoogle Scholar
- Adam A, Ciorbaru R, Petit JF, Lederer E: Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis. Proc Natl Acad Sci U S A. 1972, 69: 851-4. 10.1073/pnas.69.4.851.PubMed CentralView ArticlePubMedGoogle Scholar
- Faisal SM, Yan W, McDonough SP, Mohammed HO, Divers TJ, Chang YF: Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis. Vaccine. 2009, 27: 6129-36. 10.1016/j.vaccine.2009.08.029.View ArticlePubMedGoogle Scholar
- Tyagi JS, Sharma D: Mycobacterium smegmatis and tuberculosis. Trends Microbiol. 2002, 10: 68-9. 10.1016/S0966-842X(01)02296-X.View ArticlePubMedGoogle Scholar
- Reyrat J, Kahn D: Mycobacterium smegmatis: an absurd model for tuberculosis?. Trends Microbiol. 2001, 9: 473-4. 10.1016/S0966-842X(01)02169-2.View ArticleGoogle Scholar
- Cheadle EJ, O’Donnell D, Selby PJ, Jackson AM: Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun. 2005, 73: 784-94. 10.1128/IAI.73.2.784-794.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Snapper SB, Melton RE, Mustafa S, Kieser T, Jacobs WR: Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol. 1990, 4 (11): 1911-9. 10.1111/j.1365-2958.1990.tb02040.x.View ArticlePubMedGoogle Scholar
- Bishop PJ, Neumann G: The history of the Ziehl–Neelsen stain. Tubercle. 1970, 51: 196-206. 10.1016/0041-3879(70)90073-5.View ArticlePubMedGoogle Scholar
- Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959, 37 (8): 911-7. 10.1139/o59-099.View ArticlePubMedGoogle Scholar
- Kirby C, Gregoriadis G: Dehydration–rehydration vesicles (DRV): A new method for high yield drug entrapment in liposomes. Biotechnology. 1984, 2: 979-984. 10.1038/nbt1184-979.View ArticleGoogle Scholar
- Canadian Council on Animal Care and Use: Guide to the Care and Use of Experimental Animals. 1993, Ottawa, Ontario, 2: 175-87.Google Scholar
- Faisal SM, Chen JW, McDonough SP, Chang CF, Teng CH, Chang YF: Immunostimulatory and antigen delivery properties of liposomes made of total polar lipids from non-pathogenic bacteria leads to efficient induction of both innate and adaptive immune responses. Vaccine. 2011, 29 (13): 2381-91. 10.1016/j.vaccine.2011.01.110.View ArticlePubMedGoogle Scholar
- Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R, Fernandez S, Reyes G, Alvarez N, Garcia MA: Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine. 2011, 19: 6234-6241.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.